Fig. 2.

Neutralisation status of Anti-chikungunya virus antibodies at acute and convalescent phase. IgM and IgG antibody was quantified for 196 acute and 51 convalescent samples after one month follow-up and their neutralisation status were analysed. (a) Neutralisation status of IgM Antibody in acute phase were showing 34% (50/144 IgM positive) neutralising capacity but did not showed a significant correlation with IgM titre (b) Neutralisation status of IgG Antibody in acute phase were showing 33% (19/56 IgG positives) neutralisation capacity which is significantly correlated with IgG titre (p < 0.0001). (c) Neutralisation status of IgM Antibody in convalescent phase showing 100% (51/51 IgM positive) and a significant correlation was not observed with IgM titre. (d) Neutralisation status of IgG Antibody in convalescent phase were showing 87% (41/47 IgG positive) neutralisation and a significant correlation was observed with IgG titre (p = 0.0013). € Neutralisation capacity of acute and convalescent samples. The comparison of neutralising capacity between acute and convalescent group showed a significant difference (p 0.0186). At acute phase, 27 samples did not have neutralisation capacity; however, 20 of these samples showed neutralisation at convalescent phase.